Search Results - S. D. Trotsenko

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Current problems of postoperative radiotherapy for non-small cell lung cancer by S. D. Trotsenko, V. M. Sotnikov, G. A. Pan’shin, V. D. Chkhikvadze

    Published 2016-02-01

    The review considers the history of evolution and the present state of the problem of postoperative radiotherapy for non-small cell lung cancer. The randomized trials and meta-analyses given in recent publications provide evidence that it should be usedin radically operated patients with morphologic...

    Full description

    Get full text
    Article
  2. 2

    Impact of Postoperative Radiotherapy on Overall Survival in Patients with pN1 Non-Small Cell Lung Cancer by V. A. Solodkiy, V. M. Sotnikov, V. D. Chkhikvadze, N. V. Nudnov, S. D. Trotsenko

    Published 2022-02-01

    Objective: to comparatively analyze overall survival (OS) in patients with non-small cell lung cancer (NSCLC) with affected lymph nodes (pN1) of the lung root after surgical and combination treatment with postoperative radiotherapy (PORT). Subjects and methods. OS was studied in 310 patients with gr...

    Full description

    Get full text
    Article
  3. 3

    The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibito... by I. E. Khatkov, I. I. Andreyashkina, I. D. Trotsenko, O. N. Matveeva, V. A. Reznikov

    Published 2025-07-01

    Introduction. CDK4/6 inhibitors in combination with endocrine therapy (ET) are the current standard of care for patients with HR+ HER2- advanced and metastatic breast cancer (eBC and mBC). Evidence of the clinical efficacy of CDK4/6 inhibitors has been obtained in several randomized clinical trials...

    Full description

    Get full text
    Article
  4. 4

    MOLECULAR-GENETIC CHARACTERISTICS OF PRIMARY TUMOR AND METASTATIC LYMPHATIC NODES IN BREAST CANCER by V. K. Bozhenko, I. D. Trotsenko, E. A. Kudinova, S. G. Vardanyan, M. V. Zakharenko, V. A. Solodkiy, M. V. Makarova

    Published 2019-11-01

    The purpose of systemic treatment in patients with breast cancer is based largely on the molecular characteristics of the primary tumor, but many clinical recommendations suggest also the study of metastatic nodes with an assessment of their receptor status (estrogen receptor ER, progesterone recept...

    Full description

    Get full text
    Article
  5. 5

    BREAST CANCER TYPING USING RT-PCR ASSAY by V. K. Bozhenko, I. D. Trotsenko, E. A. Kudinova, S. G. Vardanyan, M. V. Zakharenko, V. A. Solodky, M. V. Makarova

    Published 2019-11-01

    Introduction. Adjuvant systemic therapy remains one of the main options for treating breast cancer. Results of standard immunohistochemical studies are not always a criterion for selecting systemic therapy. Nowadays, multigene expression analysis is actively used to predict the response to chemother...

    Full description

    Get full text
    Article